Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells $336,929.84 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 6,893 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $48.88, for a total transaction of $336,929.84. Following the sale, the executive vice president now owns 118,388 shares in the company, valued at approximately $5,786,805.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Rong Zhou also recently made the following trade(s):

• On Monday, August 26th, Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00.

Amphastar Pharmaceuticals Trading Down 4.7 %

NASDAQ:AMPH traded down $2.23 during mid-day trading on Wednesday, hitting $45.48. The company had a trading volume of 420,669 shares, compared to its average volume of 397,377. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The business’s fifty day moving average is $48.42 and its two-hundred day moving average is $44.34. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm has a market cap of $2.19 billion, a P/E ratio of 15.16, a P/E/G ratio of 0.92 and a beta of 0.82.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AMPH. TD Asset Management Inc lifted its holdings in Amphastar Pharmaceuticals by 67.4% during the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock worth $67,663,000 after purchasing an additional 680,976 shares during the last quarter. Epoch Investment Partners Inc. boosted its position in shares of Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after purchasing an additional 280,390 shares in the last quarter. American Century Companies Inc. raised its stake in Amphastar Pharmaceuticals by 19.7% during the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock worth $29,616,000 after buying an additional 121,764 shares during the period. Millennium Management LLC raised its stake in shares of Amphastar Pharmaceuticals by 84.6% in the second quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock worth $29,550,000 after purchasing an additional 338,653 shares during the last quarter. Finally, Boston Trust Walden Corp bought a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $26,189,000. 65.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on AMPH shares. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Finally, StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average price target of $63.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.